Advertisement
Screener

Neuphoria Therapeutics Inc. (NEUP) Restructuring Costs

2.8 / 5 stars · 68/120 Roast Me

Neuphoria Therapeutics Inc. Restructuring Costs

Neuphoria Therapeutics Inc. (NEUP) reported Restructuring Costs of $1.28 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:RestructuringCosts · last filed 2026-09-18

  • Neuphoria Therapeutics Inc. restructuring costs for the quarter ending 2026-06-30 was $0.00.
  • Neuphoria Therapeutics Inc. restructuring costs for the quarter ending 2026-03-31 was $42.41K.
  • Neuphoria Therapeutics Inc. restructuring costs for the quarter ending 2025-12-31 was $1.24M.
  • Neuphoria Therapeutics Inc. restructuring costs for the quarter ending 2025-09-30 was $0.00.
  • Neuphoria Therapeutics Inc. restructuring costs for fiscal 2026 was $1.28M.
Period endRestructuring Costs 3 monthRestructuring Costs 6 monthRestructuring Costs 9 monthRestructuring Costs 12 month
2026-06-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18
$42.41K
derived: sum of 2 quarters · filed 2026-09-18
$1.28M
derived: sum of 3 quarters · filed 2026-09-18
$1.28M
10-K · filed 2026-09-18
2026-03-31$42.41K
10-Q · filed 2026-05-15
$1.28M
derived: sum of 2 quarters · filed 2026-05-15
$1.28M
10-Q · filed 2026-05-15
2025-12-31$1.24M
10-Q · filed 2026-05-15
$1.24M
10-Q · filed 2026-02-17
2025-09-30$0.00
derived: 10-K 12 month − 3 quarters · filed 2026-09-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66